Chroman derivatives

1. A compound represented by Formula I

wherein:

—A—B— is —CH 2 —CH 2 —; —CH═CH—; —CH 2 —O—; —CH 2 —S—; or —CH 2 —N—;

n is 0 to 5;

R 1 is C 1-4 alkyl or halo-(C 1-4 )-alkyl;

R 2 is

—C(O)OR a ;

halogen or dihalovinyl;

aryl optionally substituted with substituted with one or more substituents selected from alkyl, haloalkyl, hydroxy, alkoxy, halogen, oxo, cyano, nitro, amino, —SO 2 NR 2 , and —C(O)OR;

-Het, —CH-(Het) 2 ; or —CH=Het; where Het is saturated, partially unsaturated or unsaturated heterocyclyl optionally substituted with one or more substituents selected from alkyl, haloalkyl, hydroxy, alkoxy, halogen, oxo, cyano, nitro, amino, —SO 2 NR 2 , and —C(O)OR;

R 3 is

hydrogen;

halogen;

optionally substituted C 1-6 alkyl;

C 2-20 alkenyl;

—OR;

nitro;

—(CR 2 ) m C(O)OR a ;

—(CR 2 ) m C(O)NR b R c ;

—(CR 2 ) m N(OH)C(O)NR b R c ;

—(CR 2 ) m NR b R c ;

—(CR 2 ) m NR b —SO 2 —R a ;

—(CR 2 ) m S(O) 0-2 R a ;

—(CR 2 ) m SO 2 NR b R c ;

—CR=Het, wherein Het is a saturated, partially unsaturated or unsaturated heterocycyl optionally substituted with one or more substituents selected from alkyl, haloalkyl, hydroxy, alkoxy, halogen, oxo, cyano, nitro, amino, —SO 2 NR 2 , and —C(O)OR;

cycloalkyl, aryl or saturated, partially unsaturated or unsaturated heterocyclyl, all rings optionally substituted with C 1-6 alkyl, hydroxy, alkoxy, nitro, amino, or —C(O)OR;

R 4 is hydrogen; optionally substituted C 1-4 alkyl, C 2-12 alkenyl, hydroxyalkyl, acyl, glucoside, phosphoryl, phosphoryloxyalkyl, carboxyalkylcarbonyl, aminoalkylcarbonyl, or alkylketocarbonyl;

R 5 and R 6 are independently of each other C 1-6 alkyl, C 2-20 alkenyl, or halogen;

m is 0 to 3;

R is hydrogen or C 1-4 alkyl;

R a is hydrogen, optionally substituted C 1-4 alkyl, optionally substituted C 2-12 alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, or optionally substituted heterocyclyl;

R b and R c are independently of each other hydrogen, C 1-4 alkyl, hydroxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted benzyl, or optionally substituted heterocyclyl; or R b and R c taken together with the atom to which they are attached form a 5 to 8 membered aromatic, saturated or unsaturated ring, optionally incorporating one additional atom chosen from N, O, or S and optionally substituted with a substituent selected from the group consisting of lower alkyl, halo, cyano, alkylthio, lower alkoxy, oxo, phenyl, benzyl and carboxy;

with the proviso that if —A—B— is —CH 2 —CH 2 — or —CH═CH—, and R 3 , R 5 , or R 6 are hydrogen or C 1-3 -alkyl then R 2 is not —C(O)OR, halogen, or aryl;

further provided that if R 2 is -Het and R 3 is C 1-6 -alkyl, then n=0 and Het is not 2,2-dimethyl-[1,3]dioxolan-4-yl, oxiran-2-yl, thiazole-2-yl, oxazole-2-yl, thiazole-4-yl or benzofuran-2-yl;

and further provided that if R 2 is aryl, then R 3 is not optionally substituted alkyl;

or

single stereoisomers, mixtures of stereoisomers, or pharmaceutically acceptable salts thereof.

2. The compound of claim 1 , wherein R 2 is —CH=Het, where Het is saturated or partially unsaturated heterocyclyl optionally substituted with one or more substituents selected from alkyl, haloalkyl, hydroxy, alkoxy, halogen, oxo, cyano, nitro, amino, —SO 2 NR 2 , and —C(O)OR.

3. The compound of claim 2 , wherein R 2 is 2,4-dioxo thiazolidin-5-methylene or 3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-yl)-methylene.

4. The compound of claim 3 selected from:

5-[3-(6-Methoxymethoxy-2,7,8-trimethyl-chroman-2-yl)-propylidene]-thiazolidine-2,4-dione;

5-[3-(6-Hydroxy-2,7,8-trimethyl-chroman-2-yl)-propylidene]-thiazolidine-2,4-dione; and single stereoisomers, mixtures of stereoisomers, or pharmaceutically acceptable salts thereof.

5. A pharmaceutical composition comprising a compound of claim 1 admixed with a pharmaceutically acceptable excipient.

6. A method of treating a subject suffering from neurodegenerative disorders, oxidative stress disorders or mitochondrial disorders comprising administering to said subject a therapeutically effective amount of a compound of claim 1 or stereoisomers, mixture of stereoisomers or pharmaceutically acceptable salts thereof.